Private Advisor Group LLC Has $17.93 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Private Advisor Group LLC boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 6.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 707,714 shares of the biopharmaceutical company's stock after acquiring an additional 42,238 shares during the quarter. Private Advisor Group LLC's holdings in Pfizer were worth $17,933,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the business. Norges Bank purchased a new stake in Pfizer during the 4th quarter worth about $2,328,986,000. Starboard Value LP purchased a new stake in Pfizer during the 4th quarter worth about $407,730,000. Assenagon Asset Management S.A. increased its position in Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after purchasing an additional 7,581,030 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares in the last quarter. Finally, APG Asset Management N.V. increased its position in Pfizer by 1,106.0% during the 4th quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock worth $143,967,000 after purchasing an additional 5,153,257 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on PFE shares. UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. BMO Capital Markets reduced their price objective on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Jefferies Financial Group boosted their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Morgan Stanley boosted their price target on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Finally, The Goldman Sachs Group upped their target price on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.55.

Pfizer Stock Down 0.5%

NYSE:PFE traded down $0.12 during trading hours on Friday, hitting $24.46. 36,271,002 shares of the company's stock traded hands, compared to its average volume of 41,959,930. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock's fifty day moving average price is $24.07 and its two-hundred day moving average price is $24.73. The firm has a market cap of $139.06 billion, a P/E ratio of 17.72, a P/E/G ratio of 0.89 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.82 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.03%. Pfizer's payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.